چکیده:
Neuropathic pain (NP) results from injuries or diseases of the sensory nervous system. Symptoms of this condition include spontaneous pain, hyperalgesia, and allodynia. Due to the complexity of the mechanism, conventional painkillers are ineffective. Recent preclinical research has shown promising results in treating NP with stem cells.
Despite the importance of the beneficial effects of stem cells, there remains a paucity of evidence on optimizing the dose and cell delivery routes of stem cells during NP. To this end, we evaluated two doses and routes of administration of bone marrow mesenchymal stem cells (BM-MSCs) in the chronic constriction injury (CCI)-induced neuropathic pain model. To compare doses and routes of administration (intravenous and intralesional injections), pain sensitization, oxidative stress, and astrogliosis assessments were performed.
We found that a significant reduction in pain sensitization parameters was observed on most experimental days. High-dose treatment (intravenous and intralesional injections) and low dose treatment (intralesional injection) produced an antinociceptive effect. Although the low dose (intravenous injection) decreased pain sensitization parameters, the reduction in neuropathic pain did not reach statistical significance compared to the CCI group. Our data demonstrated that intravenous and intralesional injections of BM-MSCs significantly improved oxidative stress by inhibiting the level of malondialdehyde (MDA) compared to the CCI group. In addition, intravenous and intralesional injections of BM-MSCs decreased astrogliosis in the dorsal horn of the spinal cord, as indicated by GFAP.
In conclusion, BM-MSC transplantation alleviated NP sensitization in the CCI model. These results suggest that optimized dosing and delivery routes of BM-MSCs may represent a promising therapeutic approach for neuropathic pain management.
Despite the importance of the beneficial effects of stem cells, there remains a paucity of evidence on optimizing the dose and cell delivery routes of stem cells during NP. To this end, we evaluated two doses and routes of administration of bone marrow mesenchymal stem cells (BM-MSCs) in the chronic constriction injury (CCI)-induced neuropathic pain model. To compare doses and routes of administration (intravenous and intralesional injections), pain sensitization, oxidative stress, and astrogliosis assessments were performed.
We found that a significant reduction in pain sensitization parameters was observed on most experimental days. High-dose treatment (intravenous and intralesional injections) and low dose treatment (intralesional injection) produced an antinociceptive effect. Although the low dose (intravenous injection) decreased pain sensitization parameters, the reduction in neuropathic pain did not reach statistical significance compared to the CCI group. Our data demonstrated that intravenous and intralesional injections of BM-MSCs significantly improved oxidative stress by inhibiting the level of malondialdehyde (MDA) compared to the CCI group. In addition, intravenous and intralesional injections of BM-MSCs decreased astrogliosis in the dorsal horn of the spinal cord, as indicated by GFAP.
In conclusion, BM-MSC transplantation alleviated NP sensitization in the CCI model. These results suggest that optimized dosing and delivery routes of BM-MSCs may represent a promising therapeutic approach for neuropathic pain management.
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
